Screener
G&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001649094-26-000017
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $312,779 | $148,134 |
| General and administrative | 33,071 | 32,659 |
| Total operating expenses | 345,850 | 180,793 |
| Loss from operations | (345,850) | (180,793) |
| Other income, net: | ||
| Interest income | 26,610 | 32,935 |
| Other income (expense) | (1,382) | 7,140 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Vaxcyte, Inc.'s G&A?
- Vaxcyte, Inc. (PCVX) reported G&A of $33.07M in Q1 2026.
- How has Vaxcyte, Inc.'s G&A changed year-over-year?
- Vaxcyte, Inc.'s G&A increased by 1.3% year-over-year, from $32.66M to $33.07M.
- What is the long-term trend for Vaxcyte, Inc.'s G&A?
- Over 4 years (2021 to 2025), Vaxcyte, Inc.'s G&A has grown at a 50.4% compound annual growth rate (CAGR), from $25.26M to $129.37M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Vaxcyte, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude